

[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
David Lebowitz Initiated (BMRN) at Hold and Held Target at $116 on, Feb 21st, 2023
David Lebowitz of Citigroup, Initiated "BioMarin Pharmaceutical Inc." (BMRN) at Hold and Held Target at $116 on, Feb 21st, 2023.
David has made no other calls on BMRN in the last 4 months.
There are 9 other peers that have a rating on BMRN. Out of the 9 peers that are also analyzing BMRN, 3 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Kostas Biliouris of "BMO Capital" Initiated at Hold and Held Target at $107 on, Monday, January 30th, 2023
- Whitney Ijem of "Canaccord Genuity" Initiated at Hold and Held Target at $119 on, Wednesday, January 18th, 2023
- Andreas Argyrides of "Wedbush" Maintained at Hold with Increased Target to $83 on, Wednesday, January 11th, 2023
These are the ratings of the 6 analyists that currently disagree with David
- Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $130 on, Friday, February 3rd, 2023
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $132 on, Tuesday, January 24th, 2023
- Akash Tewari of "Jefferies" Maintained at Strong Buy with Increased Target to $120 on, Tuesday, November 29th, 2022
- Leland Gershell of "Oppenheimer" Upgraded from Hold to Buy and Increased Target to $110 on, Monday, October 31st, 2022
- Tiago Fauth of "Credit Suisse" Maintained at Buy with Decreased Target to $110 on, Thursday, October 27th, 2022
- Jessica Fye of "JP Morgan" Maintained at Buy with Decreased Target to $112 on, Monday, October 24th, 2022
Contributing Sources